35 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
22299588	33	Inhibition of the ß-class carbonic anhydrases from Mycobacterium tuberculosis with carboxylic acids.	Universit?? Degli Studi Di Firenze
24072711	28	The SUMO1-E67 interacting loop peptide is an allosteric inhibitor of the dipeptidyl peptidases 8 and 9.	Georg-August-University of Goettingen
23853092	3	Histone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophages.	University of Queensland
19746963	43	Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.	Purdue University
18760609	66	Achiral oligoamines as versatile tool for the development of aspartic protease inhibitors.	Philipps University Marburg
19473017	12	Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.	Purdue University
18783203	15	Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.	Purdue University
16277992	12	Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.	Georgia State University
16634628	42	Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.	Johnson & Johnson Pharmaceutical
10387041	7	Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease.	University of Queensland
16913714	4	Structure-Based Design of Novel HIV-1 Protease Inhibitors To Combat Drug Resistance.	Purdue University
16904316	16	New, potent P1/P2-morpholinone-based HIV-protease inhibitors.	Glaxosmithkline
16644213	39	Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-acyl aromatic alpha-amino acids.	Ambrilia Biopharma
15713418	42	Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies.	Pharmacor
15225709	37	Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-disubstituted ureas.	Procyon Biopharma
14643311	43	Lysine sulfonamides as novel HIV-protease inhibitors: optimization of the Nepsilon-acyl-phenyl spacer.	Pharmacor
14505679	43	1,2,5,6-tetra-O-benzyl-D-mannitol derivatives as novel HIV protease inhibitors.	Pharmacor
8784449	203	Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.	Dupont Pharmaceuticals
16480871	12	Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.	Purdue University
9871583	7	Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.	University of Illinois At Chicago
15887965	10	Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.	University of Illinois At Chicago
12113826	23	Novel cyclourethane-derived HIV protease inhibitors: a ring-closing olefin metathesis based strategy.	University of Illinois At Chicago
12419377	5	Novel spirocyclic pyrrolidones as P2/P1 mimetics in potent inhibitors of HIV-1 protease.	Glaxosmithkline
10866371	12	Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.	Glaxosmithkline
15482949	17	Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties.	Glaxosmithkline
15482948	7	Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.	Glaxosmithkline
15582415	17	Optimization of pyrrolidinone based HIV protease inhibitors.	Glaxosmithkline
15975788	23	Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors.	Glaxosmithkline
16480273	12	Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.	Georgia State University
12699382	4	An ethylenamine inhibitor binds tightly to both wild type and mutant HIV-1 proteases. Structure and energy study.	Academy of Sciences of The Czech Republic
14690411	40	Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.	University of Florida College of Medicine
12723947	10	Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.	University of Pennsylvania
10508432	12	Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitors.	Uppsala University